Comparison of new point-of-care troponin assay with high sensitivity troponin in diagnosing myocardial infarction.

OBJECTIVES The aim of this study is to compare a new improved point of care cardiac troponin assay (new POC-cTnI) with 1. its predecessor (old POC-cTnI) and 2. a high sensitivity assay (hs-cTnI) for the diagnosis of acute myocardial infarction (AMI) and for major adverse cardiac events (MACE) by 30 days. METHODS This is a single centre observational study, set in Christchurch Hospital, New Zealand. Patients presenting to the emergency department with non-traumatic chest pain underwent blood sampling at 0 h and 2h post presentation for analysis with the 3 cTnI assays for the outcome of AMI and for analysis using an accelerated diagnostic protocol (ADP-normal 2h troponins, normal electrocardiograms and Thrombolysis In Myocardial Infarction (TIMI) score of 0 or ≤ 1) for 30 day MACE. RESULTS Of 962 patients, 220 (22.9%) had AMI. Old POC-cTnI was least sensitive at 70.0% (65.4-73.9%) by 2h (p<0.001). New POC-cTnI, sensitivity 93.6% (89.9-96.2%) had similar sensitivity to hs-cTnI, sensitivity 95.0% (91.5-97.3%) (p = 0.508). There were 231 (24.0%) patients with 30 day MACE. When used as part of the ADP, all assays had 100% (98.0-100%) sensitivity using TIMI = 0. Sensitivities of new POC-cTnI ADP, 98.3% (95.4-99.4%), old POC-cTnI, 96.5% (93.2-98.4%) and hs-cTnI, 98.7% (96.0-99.7%) were similar (p = 0.063-0.375) using TIMI ≤ 1. CONCLUSIONS A new POC-cTnI has improved sensitivity for AMI and MACE compared with its predecessor and comparable sensitivity to a high sensitivity assay. Now that sensitivities of the POC assay are improved, the new assay may be a useful alternative to central laboratory assays when rapid turn-around times are not possible.

[1]  C. Reid,et al.  Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. , 2013, Journal of the American College of Cardiology.

[2]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[4]  James McCord,et al.  Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. , 2010, Circulation.

[5]  F. Rutten,et al.  Point-of-care tests in suspected acute myocardial infarction: a systematic review. , 2013, International journal of cardiology.

[6]  F. Apple,et al.  Decreased patient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[7]  Robert H Christenson,et al.  Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing? , 2002, Clinical biochemistry.

[8]  F. Verheugt,et al.  Lack of concordance between a rapid bedside and conventional laboratory method of cardiac troponin testing: impact on risk stratification of patients suspected of acute coronary syndrome. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[9]  L. Wallentin,et al.  Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. , 2004, Clinical chemistry.

[10]  D. Armbruster,et al.  Limit of blank, limit of detection and limit of quantitation. , 2008, The Clinical biochemist. Reviews.

[11]  P. Collinson,et al.  Point-of-care testing: a cardiologist's view. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[12]  C. Reid,et al.  2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. , 2012, Journal of the American College of Cardiology.

[13]  Simon Dixon,et al.  Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel Assay of cardiac markers (RATPAC) trial. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[14]  C. Price,et al.  Testing at the Point-of-Care: Errors of Omission in the Patient Care Pathway , 2011 .

[15]  A. Brown,et al.  Comprehensive standardized data definitions for acute coronary syndrome research in emergency departments in Australasia , 2010, Emergency medicine Australasia : EMA.

[16]  P. Venge,et al.  Clinical performance of a new point-of-care cardiac troponin I assay compared to three laboratory troponin assays. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[17]  T. Aufderheide,et al.  Standardized reporting guidelines for studies evaluating risk stratification of emergency department patients with potential acute coronary syndromes. , 2004, Annals of emergency medicine.

[18]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[19]  R. Troughton,et al.  A new improved accelerated diagnostic protocol safely identifies low-risk patients with chest pain in the emergency department. , 2012, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[20]  J. Attia,et al.  Point of care troponin decreases time in the emergency department for patients with possible acute coronary syndrome: a randomised controlled trial , 2010, Emergency Medicine Journal.

[21]  P. Dodds,et al.  Is it safe to discharge patients from accident and emergency using a rapid point of care Triple Cardiac Marker test to rule out acute coronary syndrome in low to intermediate risk patients presenting with chest pain? , 2008, European journal of internal medicine.

[22]  D. Giannessi,et al.  Plasma Brain Natriuretic Peptide Measured by Fully-Automated Immunoassay and by Immunoradiometric Assay Compared , 2001, Clinical chemistry and laboratory medicine.

[23]  James McCord,et al.  Ninety-Minute Exclusion of Acute Myocardial Infarction By Use of Quantitative Point-of-Care Testing of Myoglobin and Troponin I , 2001, Circulation.

[24]  P. Trerotoli,et al.  Appropriateness of point-of-care testing (POCT) in an emergency department. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[25]  Fred S Apple,et al.  Diagnostic performance of four point of care cardiac troponin I assays to rule in and rule out acute myocardial infarction. , 2013, Clinical biochemistry.

[26]  Brandy Drake.  A 2-h Diagnostic Protocol to Assess Patients with Chest Pain Symptoms in the Asia-Pacific region (ASPECT): A Prospective Observational Validation Study , 2011 .

[27]  Mike Bradburn,et al.  The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department , 2010, Heart.

[28]  B. Lindahl,et al.  Early and late outcome prediction of death in the emergency room setting by point-of-care and laboratory assays of cardiac troponin I. , 2010, American heart journal.

[29]  Michael Christ,et al.  Cardiac troponin: a critical review of the case for point-of-care testing in the ED. , 2012, The American journal of emergency medicine.

[30]  P O Collinson,et al.  Analytical performance of the N terminal pro B type natriuretic peptide (NT‐proBNP) assay on the Elecsys™ 1010 and 2010 analysers , 2004, European journal of heart failure.

[31]  M. Frenneaux,et al.  Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. , 2004, Clinical chemistry.

[32]  Zhen Yang,et al.  Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction. , 2006, Clinical biochemistry.